NCT02373150View on ClinicalTrials.gov

Safety, Tolerability and PK of Imeglimin in Japanese Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Imeglimin

DRUG

Placebo

Trial Locations (1)

Unknown

Hammersmith Medicines Research (HMR), London

Sponsors

Lead Sponsor

Poxel SA
All Listed Sponsors
lead

Poxel SA

INDUSTRY

NCT02373150 - Safety, Tolerability and PK of Imeglimin in Japanese Volunteers | Biotech Hunter | Biotech Hunter